INmune Bio

David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access. INmune is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patients’ NK cells (...